D.A. Davidson & CO. Reduces Stock Position in Regeneron Pharmaceuticals, Inc. $REGN

D.A. Davidson & CO. reduced its holdings in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 16.8% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 609 shares of the biopharmaceutical company’s stock after selling 123 shares during the quarter. D.A. Davidson & CO.’s holdings in Regeneron Pharmaceuticals were worth $320,000 at the end of the most recent quarter.

Other institutional investors also recently modified their holdings of the company. Schwartz Investment Counsel Inc. lifted its stake in Regeneron Pharmaceuticals by 21.9% in the 2nd quarter. Schwartz Investment Counsel Inc. now owns 975 shares of the biopharmaceutical company’s stock worth $512,000 after purchasing an additional 175 shares in the last quarter. Klingman & Associates LLC purchased a new stake in Regeneron Pharmaceuticals in the 2nd quarter worth approximately $201,000. Phoenix Financial Ltd. lifted its stake in Regeneron Pharmaceuticals by 12.3% in the 2nd quarter. Phoenix Financial Ltd. now owns 583 shares of the biopharmaceutical company’s stock worth $306,000 after purchasing an additional 64 shares in the last quarter. Cidel Asset Management Inc. lifted its stake in Regeneron Pharmaceuticals by 20.4% in the 2nd quarter. Cidel Asset Management Inc. now owns 461 shares of the biopharmaceutical company’s stock worth $242,000 after purchasing an additional 78 shares in the last quarter. Finally, International Assets Investment Management LLC lifted its stake in Regeneron Pharmaceuticals by 30.0% in the 2nd quarter. International Assets Investment Management LLC now owns 724 shares of the biopharmaceutical company’s stock worth $380,000 after purchasing an additional 167 shares in the last quarter. 83.31% of the stock is currently owned by hedge funds and other institutional investors.

Regeneron Pharmaceuticals Price Performance

Shares of NASDAQ:REGN opened at $654.04 on Friday. The company has a debt-to-equity ratio of 0.09, a current ratio of 4.06 and a quick ratio of 3.72. Regeneron Pharmaceuticals, Inc. has a one year low of $476.49 and a one year high of $883.15. The company’s fifty day moving average price is $580.56 and its 200-day moving average price is $564.66. The firm has a market capitalization of $69.32 billion, a price-to-earnings ratio of 15.66, a PEG ratio of 2.03 and a beta of 0.31.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its earnings results on Tuesday, October 28th. The biopharmaceutical company reported $11.83 EPS for the quarter, beating the consensus estimate of $9.73 by $2.10. Regeneron Pharmaceuticals had a net margin of 32.13% and a return on equity of 13.76%. The company had revenue of $3.75 billion for the quarter, compared to analyst estimates of $3.57 billion. During the same quarter last year, the firm earned $12.46 EPS. The firm’s quarterly revenue was up .9% compared to the same quarter last year. On average, equities research analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, December 5th. Investors of record on Thursday, November 20th will be issued a dividend of $0.88 per share. The ex-dividend date of this dividend is Thursday, November 20th. This represents a $3.52 annualized dividend and a dividend yield of 0.5%. Regeneron Pharmaceuticals’s dividend payout ratio (DPR) is currently 8.43%.

Wall Street Analysts Forecast Growth

Several analysts have issued reports on the stock. Cantor Fitzgerald increased their target price on shares of Regeneron Pharmaceuticals from $678.00 to $740.00 and gave the stock an “overweight” rating in a research note on Wednesday. Guggenheim increased their target price on shares of Regeneron Pharmaceuticals from $815.00 to $865.00 and gave the stock a “buy” rating in a research note on Wednesday. Weiss Ratings reiterated a “hold (c-)” rating on shares of Regeneron Pharmaceuticals in a research note on Wednesday, October 8th. Morgan Stanley lowered their target price on shares of Regeneron Pharmaceuticals from $761.00 to $756.00 and set an “overweight” rating on the stock in a research note on Friday, October 10th. Finally, Raymond James Financial raised shares of Regeneron Pharmaceuticals to a “moderate buy” rating in a report on Tuesday, September 2nd. Three investment analysts have rated the stock with a Strong Buy rating, seventeen have issued a Buy rating, seven have issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, Regeneron Pharmaceuticals presently has an average rating of “Moderate Buy” and a consensus target price of $813.78.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.